Circulating cell-free DNA-based biomarkers for prognostication and disease monitoring in adrenocortical carcinoma
European Journal of Endocrinology · 02.03.2024 · 190 (3) · 234-247
DOI: 10.1093/ejendo/lvae022 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Endocrinology, online erschienen am 07.03.2024. Verfasst von Juliane Lippert und 13 weiteren Autor:innen. Beteiligte Einrichtung: Division of Endocrinology and Diabetes, Department of Medicine, University Hospital, University of Wuerzburg, 97080 Wuerzburg, Germany. Hauptthemen laut MEDLINE: Adrenocortical Carcinoma, Cell-Free Nucleic Acids, Adrenal Cortex Neoplasms. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Deutsche Krebshilfe, AMEND, European Reference Network on Rare Endocrine Conditions.
Abstract (Originalsprache)
Objective
Adrenocortical carcinoma (ACC) is a rare aggressive cancer with heterogeneous behaviour. Disease surveillance relies on frequent imaging, which comes with significant radiation exposure. The aim of the study was to investigate the role of circulating cell-free DNA (ccfDNA)-related biomarkers (BMs) for prognostication and monitoring of ACC. Design and Methods We investigated 34 patients with ACC and 23 healthy subjects (HSs) as controls. Circulating cell-free DNA was extracted by commercial kits and ccfDNA concentrations were quantified by fluorimeter (BM1). Targeted sequencing was performed using a customized panel of 27 ACC-specific genes. Leucocyte DNA was used to discriminate somatic variants (BM2), while tumour DNA was sequenced in 22/34 cases for comparison. Serial ccfDNA samples were collected during follow-up in 19 ACC patients (median period 9 months) and analysed in relationship with standard radiological imaging.
Results
Circulating cell-free DNA concentrations were higher in ACC than HS (mean ± SD, 1.15 ± 1.56 vs 0.05 ± 0.05 ng/µL, P < .0001), 96% of them being above the cut-off of 0.146 ng/µL (mean HS + 2 SD, positive BM1). At ccfDNA sequencing, 47% of ACC showed at least 1 somatic mutation (positive BM2). A combined ccfDNA-BM score was strongly associated with both progression-free and overall survival (hazard ratio [HR] = 2.63; 95% CI, 1.13-6.13; P = .010, and HR = 5.98; 95% CI, 2.29-15.6; P = .0001, respectively). During disease monitoring, positive BM2 showed the best specificity (100%) and sensitivity (67%) to detect ACC recurrence or progress compared with BM1. Conclusion ccfDNA-related BMs are frequently detected in ACC patients and represent a promising, minimally invasive tool to predict clinical outcome and complement surveillance imaging. Our findings will be validated in a larger cohort of ACCs with long-term follow-up.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Endocrinology and Diabetes, Department of Medicine, University Hospital, University of Wuerzburg, 97080 Wuerzburg, Germany.
- Institute of Human Genetics, University of Wuerzburg, 97070 Wuerzburg, Germany.
- Institute of Metabolism and System Research, University of Birmingham, B152TT Birmingham, United Kingdom.
- Core Unit Bioinformatics, Comprehensive Cancer Center Mainfranken, University of Wuerzburg, 97070 Wuerzburg, Germany.
- Centre for Endocrinology, Diabetes and Metabolism (CEDAM), Birmingham Health Partners, B152TT Birmingham, United Kingdom.
- NIHR Birmingham Biomedical Research Centre, University of Birmingham, University Hospitals Birmingham NHS Foundation Trust, B152GW Birmingham, United Kingdom.
ORCID-Profile: Laura-Sophie Landwehr, Alessandro Prete, Yasir S Elhassan, Wiebke Arlt, Martin Fassnacht, Barbara Altieri, Cristina L Ronchi
Förderung
- Deutsche Krebshilfe
- AMEND
- European Reference Network on Rare Endocrine Conditions
- National Institute for Health
- Care Research
- Birmingham Biomedical Research Centre
- University Hospitals Birmingham
- NHS Foundation Trust
Zitieren
APA
Lippert, J., Smith, G., Appenzeller, S., Landwehr, L. S., Prete, A., Steinhauer, S., Asia, M., Urlaub, H., Elhassan, Y. S., Kircher, S., Arlt, W., Fassnacht, M., Altieri, B., & Ronchi, C. L. (2024). Circulating cell-free DNA-based biomarkers for prognostication and disease monitoring in adrenocortical carcinoma. European Journal of Endocrinology, 190(3), 234-247. https://doi.org/10.1093/ejendo/lvae022
Vancouver
Lippert J, Smith G, Appenzeller S, Landwehr LS, Prete A, Steinhauer S, et al. Circulating cell-free DNA-based biomarkers for prognostication and disease monitoring in adrenocortical carcinoma. European Journal of Endocrinology. 2024;190(3):234-247. doi:10.1093/ejendo/lvae022
BibTeX
@article{Lippert2024,
author = {Lippert, Juliane and Smith, Gabrielle and Appenzeller, Silke and Landwehr, Laura-Sophie and Prete, Alessandro and Steinhauer, Sonja and Asia, Miriam and Urlaub, Hanna and Elhassan, Yasir S and Kircher, Stefan and Arlt, Wiebke and Fassnacht, Martin and Altieri, Barbara and Ronchi, Cristina L},
title = {Circulating cell-free DNA-based biomarkers for prognostication and disease monitoring in adrenocortical carcinoma},
journal = {European Journal of Endocrinology},
year = {2024},
volume = {190},
number = {3},
pages = {234--247},
doi = {10.1093/ejendo/lvae022}
}
EUVIMED